Lacerta Therapeutics
John Spence has a work experience that includes the roles of a Senior Principal Scientist at Lacerta Therapeutics from September 2021 to present, a Manufacturing Supervisor at Arranta Bio from November 2020 to June 2021, and a Bio manufacturing Supervisor at Ology Bioservices, Inc. from April 2018 to September 2020.
From 2008 to 2010, John Spence attended City College where they obtained an Associate of Science (AS) degree in the field of study of Health Services/Allied Health/Health Sciences, General.
Lacerta Therapeutics
Lacerta Therapeutics is a clinical stage gene therapy company using a constellation of proprietary adeno-associated virus (AAV) vector technologies to develop treatments for central nervous system and lysosomal storage diseases. With unmatched scientific expertise and depth in the development, production, and application of AAV vectors, LacertaTherapeutics is advancing its clinical programs using its proprietary capsid variants and scalable vector manufacturing platform. The experience and accomplishments of the Lacerta Therapeutics founders are unsurpassed in AAV gene therapy. In addition to world-class basic AAV vector development and gene therapy clinical trial expertise, our team brings to bear individuals with novel insight into developing novel, targeted neurological and lysosomal storage disease treatments.